Deeter Investments
CYTK icon

Deeter Investments’s Cytokinetics CYTK Stock Holding History

Deeter Investments’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.09M Sell
12,739
-80,000
-86% -$5.74M 0.15% 80
2026
Q1 		$6.11M Sell
92,739
-6,000
-6% -$381K 0.69% 34
2025
Q4 		$6.27M Buy
+98,739
New +$6.14M 1.34% 25

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Deeter Investments's CYTK Position: Q2 2026 in Review

Deeter Investments reduced its Cytokinetics (CYTK) stake by 86% in Q2 2026, selling an estimated $5.74M and leaving 12,739 shares worth $1.09M. The position accounts for 0.15% of the portfolio, ranked #80.

Deeter Investments first reported a position in CYTK in Q4 2025 and has held it in 3 quarters since. The position peaked at $6.27M in Q4 2025. 486 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Deeter Investments held 12,739 shares of Cytokinetics worth $1.09M as of Q2 2026.
  • Deeter Investments sold 80,000 Cytokinetics shares in Q2 2026, an estimated $5.74M.
  • Cytokinetics made up 0.15% of Deeter Investments's portfolio in Q2 2026, its #80 holding.
  • Deeter Investments first reported a position in Cytokinetics in Q4 2025 and has held it in 3 quarters since.
  • Deeter Investments's Cytokinetics position peaked at $6.27M in Q4 2025.
  • 486 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Deeter Investments's 13F filing for Q2 2026, filed 8 Oct 2026.